Difference between revisions of "Melanoma, KIT-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable sortable" style="width: 75%; text-align:center;"" to "{| class="wikitable sortable" style="width: 60%; text-align:center;"") |
|||
| Line 20: | Line 20: | ||
|} | |} | ||
===Regimen variant #1, pre-planned escalation {{#subobject:662612|Variant=1}}=== | ===Regimen variant #1, pre-planned escalation {{#subobject:662612|Variant=1}}=== | ||
| − | {| class="wikitable sortable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
!style="width: 33%"|Years of enrollment | !style="width: 33%"|Years of enrollment | ||
| Line 45: | Line 45: | ||
===Regimen variant #2 {{#subobject:d1f61b|Variant=1}}=== | ===Regimen variant #2 {{#subobject:d1f61b|Variant=1}}=== | ||
| − | {| class="wikitable sortable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
!style="width: 33%"|Years of enrollment | !style="width: 33%"|Years of enrollment | ||
Revision as of 01:10, 1 July 2021
| Section editor | |
|---|---|
 |
Elizabeth Buchbinder, MD Dana-Farber Cancer Institute Boston, MA |
Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.
1 regimens on this page
2 variants on this page
|
Advanced or metastatic disease, TKI-naive
Imatinib monotherapy
| back to top |
Regimen variant #1, pre-planned escalation
| Study | Years of enrollment | Evidence |
|---|---|---|
| Hodi et al. 2013 (BUS255) | 2006-2011 | Phase II |
Biomarker eligibility criteria
- Gene: KIT
- Alteration: amplification and mutation
- Acceptable methods of measurement: PCR or HPLC
Targeted therapy
- Imatinib (Gleevec) as follows:
- Starting dose: 400 mg PO once per day
- Upon progression: 400 mg PO twice per day
Continued indefinitely
Regimen variant #2
| Study | Years of enrollment | Evidence |
|---|---|---|
| Carvajal et al. 2011 (MSKCC 07-014) | 2007-2010 | Phase II |
Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.
Biomarker eligibility criteria
- Gene: KIT
- Alteration: amplification or mutation
Targeted therapy
- Imatinib (Gleevec) 400 mg PO once or twice per day
Continued indefinitely
References
- MSKCC 07-014: Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. link to original article contains protocol link to PMC article PubMed NCT00470470
- BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article contains verified protocol link to PMC article PubMed NCT00424515